药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688046 药康生物

交易中 05-17 14:12:25

{"stockData":{"symbol":"688046","market":"SH","secType":"STK","nameCN":"药康生物","latestPrice":11.5,"timestamp":1715926345000,"preClose":11.48,"halted":0,"volume":2461186,"delay":0,"floatShares":204000000,"shares":409999999,"eps":0.3838,"marketStatus":"交易中","marketStatusCode":2,"change":0.02,"latestTime":"05-17 14:12:25","open":11.57,"high":11.75,"low":11.41,"amount":28503200,"amplitude":0.0296,"askPrice":11.51,"askSize":5,"bidPrice":11.5,"bidSize":22,"shortable":0,"etf":0,"ttmEps":0.3838,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1715929200000},"adr":0,"adjPreClose":11.48,"symbolType":"stock_kcb","openAndCloseTimeList":[[1715909400000,1715916600000],[1715922000000,1715929200000]],"highLimit":12.63,"lowLimit":10.33,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":410000000,"pbRate":2.21,"roa":"--","roe":"1.39%","epsLYR":0.39,"committee":0.533333,"marketValue":4715000000,"floatMarketCap":2345000000,"peRate":29.963523,"changeRate":0.0017,"turnoverRate":0.0121,"status":0},"requestUrl":"/m/hq/s/688046/","defaultTab":"news","newsList":[{"id":"2436939310","title":"药康生物（688046）5月16日主力资金净买入27.70万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2436939310","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2436939310?lang=zh_cn&edition=full","pubTime":"2024-05-17 07:52","pubTimestamp":1715903569,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月16日收盘，药康生物报收于11.48元，下跌1.96%，换手率2.09%，成交量4.26万手，成交额4943.65万元。近5日资金流向一览见下表：药康生物融资融券信息显示，融资方面，当日融资买入300.23万元，融资偿还126.13万元，融资净买入174.1万元，连续3日净买入累计355.22万元。药康生物主营业务：实验动物模型的研发创制、生产销售及相关技术服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700010879.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435623304","title":"药康生物05月16日主力资金流入8万元 连续3日加仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2435623304","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435623304?lang=zh_cn&edition=full","pubTime":"2024-05-16 15:18","pubTimestamp":1715843909,"startTime":"0","endTime":"0","summary":"05月16日, 药康生物股价跌1.96%，报收11.48元，成交金额4943万元，换手率2.09%，振幅3.59%，量比0.86。药康生物今日主力资金净流入8万元，连续3日净流入，上一交易日主力净流入203万元，今日环比减少96.06%。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为40.00%，平均涨幅为3.04%。该股近5个交易日下跌11.49%，主力资金累计净流入804万元；近20日主力资金累计净流入77万元，其中净流入天数为8日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516152859876f7930&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240516152859876f7930&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435838906","title":"药康生物05月15日获主力加仓203万元 环比增加3283.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2435838906","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2435838906?lang=zh_cn&edition=full","pubTime":"2024-05-15 15:19","pubTimestamp":1715757550,"startTime":"0","endTime":"0","summary":"05月15日, 药康生物股价跌3.38%，报收11.71元，成交金额4727万元，换手率1.97%，振幅3.88%，量比0.80。药康生物今日主力资金净流入203万元，上一交易日主力净流入6万元，今日环比增加3283.33%。|05月15日主力加仓幅度前10个股||#|股票简称|主力净额占比|#|*ST博信|4.65%|#|上工申贝|4.58%|#|新研股份|3.68%|#|蓝箭电子|3.52%|#|南矿集团|3.49%|#|*ST大药|2.92%|#|通富微电|2.61%|#|博隆技术|2.56%|#|ST元成|2.46%|#|南京商旅|2.31%|药康生物所在的医疗服务行业，今日主力净流出2.81亿元，行业排名17/124。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405151534508b0a5bca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405151534508b0a5bca&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435199523","title":"药康生物大跌5.01% 近半年6家券商增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2435199523","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2435199523?lang=zh_cn&edition=full","pubTime":"2024-05-13 13:50","pubTimestamp":1715579446,"startTime":"0","endTime":"0","summary":"05月13日，药康生物股价大幅下跌，截至13点50分，药康生物下跌5.01%，报11.95元/股，成交6335万元，换手率2.54%。资金动向截止发稿，药康生物获得主力净流出406万元，其中超大单流出564万元，大单流入159万元。北向资金方面，药康生物05月10日获得北向资金减持53.72万股，截至05月10日，北向资金当前共持有药康生物236.29万股，市值2823万元，持股占流通股比为1.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405131350597a598083&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405131350597a598083&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434384290","title":"药康生物获国元证券买入评级，收入保持稳健增长，看好未来业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2434384290","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2434384290?lang=zh_cn&edition=full","pubTime":"2024-05-12 14:14","pubTimestamp":1715494453,"startTime":"0","endTime":"0","summary":"5月12日，药康生物获国元证券买入评级，近一个月药康生物获得8份研报关注。研报预计“斑点鼠”、“药筛鼠”等项目的快速推进，公司商品化小鼠品系资源不断丰富，叠加公司布点的推进和开拓力度的加大，看好公司业绩持续修复。研报认为，公司持续高强度投入研发，持续推进“野化鼠计划”、“无菌鼠及悉生鼠计划”、“斑点鼠计划”、“药筛鼠计划”等多个研发项目，看好公司未来业绩增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405121414178afd5242&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405121414178afd5242&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434384676","title":"国元证券：给予药康生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2434384676","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434384676?lang=zh_cn&edition=full","pubTime":"2024-05-12 14:02","pubTimestamp":1715493745,"startTime":"0","endTime":"0","summary":"国元证券股份有限公司马云涛,朱仕平近期对药康生物进行研究并发布了研究报告《2023年报及2024年一季度报告点评：收入保持稳健增长，看好未来业绩增长》，本报告对药康生物给出买入评级，当前股价为12.58元。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有11家机构给出评级，买入评级6家，增持评级5家；过去90天内机构目标均价为15.97。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051200001419.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434617804","title":"药康生物(688046)2023年度及2024年一季度报告点评：收入保持稳健增长 看好未来业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2434617804","media":"国元证券","top":-1,"share":"https://www.laohu8.com/m/news/2434617804?lang=zh_cn&edition=full","pubTime":"2024-05-12 08:04","pubTimestamp":1715472257,"startTime":"0","endTime":"0","summary":"事件：药康生物于近日发布2023 年报及2024 年一季度报告：2023 年公司实现收入6.2 亿，主要系公司业务持续快速发展，其中商品化模型销售业务和功能药效业务收入分别同比增长13.6%和36.1%，归母净利润1.6亿，扣非归母净利润1.1 亿，主要系公司目前仍处业务扩张期，持续高强度研发投入、加大海外市场开拓力度、生产人员扩招、新产能投产后折旧摊销增加等原因致使公司利润短期承压。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240512080423875cad38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240512080423875cad38&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433721747","title":"药康生物获华安证券买入评级，国内设施布局完成，海外收入高速增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2433721747","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2433721747?lang=zh_cn&edition=full","pubTime":"2024-05-08 21:44","pubTimestamp":1715175867,"startTime":"0","endTime":"0","summary":"2024年5月8日，药康生物获华安证券买入评级，近一个月药康生物获得7份研报关注。研报认为，国内设施布局完成，覆盖了所有国内生物医药产业集群，进一步增强对于华北市场、上海区域、粤港澳大湾区的服务能力，市占率有望持续提升。海外设施建设稳步推进，加速拓展市场。产能方面，公司首个海外设施落地SanDiego，设施已于2024Q1启用，随着美国设施的投产，能够更为快捷地响应客户需求，提升服务能力，海外市场有望加速拓展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082144318ae8e388&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405082144318ae8e388&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433726510","title":"华安证券：给予药康生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2433726510","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433726510?lang=zh_cn&edition=full","pubTime":"2024-05-08 21:11","pubTimestamp":1715173865,"startTime":"0","endTime":"0","summary":"华安证券股份有限公司谭国超近期对药康生物进行研究并发布了研究报告《国内设施布局完成，海外收入高速增长》，本报告对药康生物给出买入评级，当前股价为12.81元。维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有10家机构给出评级，买入评级5家，增持评级5家；过去90天内机构目标均价为15.97。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050800039082.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433735932","title":"药康生物(688046)：业绩保持稳健增长 境外业务将继续为公司贡献业绩弹性","url":"https://stock-news.laohu8.com/highlight/detail?id=2433735932","media":"华西证券","top":-1,"share":"https://www.laohu8.com/m/news/2433735932?lang=zh_cn&edition=full","pubTime":"2024-05-07 18:24","pubTimestamp":1715077481,"startTime":"0","endTime":"0","summary":"分析判断:业绩保持稳健增长，境外业务将继续为公司贡献业绩弹性公司23 年实现收入6.22 亿元，同比增长20.45%、24Q1 实现收入1.57 亿元，同比增长11.96%，业绩延续快速增长。 境外业务为公司贡献业绩弹性。公司23 年境外业务实现收入0.93 亿元，同比增长39.94%，展望未来考虑到首个美国San Diego 产能于24Q1 投产和持续强化国际化市场拓展，预期境外业务将延续高速增长；公司境内业务23年实现收入5.29 亿元，同比增长17.70%，保持稳健快速增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050718244387dc17d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050718244387dc17d8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433529082","title":"【机构调研记录】金元顺安基金调研药康生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2433529082","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433529082?lang=zh_cn&edition=full","pubTime":"2024-05-07 08:02","pubTimestamp":1715040178,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月6日披露的机构调研信息，金元顺安基金近期对1家上市公司进行了调研，相关名单如下：1）药康生物 个股亮点：药康生物是专注实验动物模型的研发创制、生产的高新技术企业，开发拥有自主知识产权的创新小鼠模型，是CRO上游，为CXO企业及创新药企提供基础服务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050700008180.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433252945","title":"【机构调研记录】富荣基金调研药康生物、江山欧派等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2433252945","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433252945?lang=zh_cn&edition=full","pubTime":"2024-05-07 08:02","pubTimestamp":1715040137,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月6日披露的机构调研信息，富荣基金近期对3家上市公司进行了调研，相关名单如下：1）药康生物 个股亮点：药康生物是专注实验动物模型的研发创制、生产的高新技术企业，开发拥有自主知识产权的创新小鼠模型，是CRO上游，为CXO企业及创新药企提供基础服务。2）江山欧派 个股亮点：江山转债于2021-07-01上市；公司已投资华飞安防公司以扩充产品线。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050700008127.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433358252","title":"【机构调研记录】国新国证基金调研药康生物、阿特斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2433358252","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433358252?lang=zh_cn&edition=full","pubTime":"2024-05-07 08:02","pubTimestamp":1715040122,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月6日披露的机构调研信息，国新国证基金近期对2家上市公司进行了调研，相关名单如下：1）药康生物 个股亮点：药康生物是专注实验动物模型的研发创制、生产的高新技术企业，开发拥有自主知识产权的创新小鼠模型，是CRO上游，为CXO企业及创新药企提供基础服务。旗下最近一年表现最佳的公募基金产品为国新国证雄安建设发展三年定开债，最新单位净值为1.09，近一年增长4.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405070803468ae2d6c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405070803468ae2d6c5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433540932","title":"【机构调研记录】博远基金调研药康生物、江山欧派","url":"https://stock-news.laohu8.com/highlight/detail?id=2433540932","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433540932?lang=zh_cn&edition=full","pubTime":"2024-05-07 08:01","pubTimestamp":1715040114,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月6日披露的机构调研信息，博远基金近期对2家上市公司进行了调研，相关名单如下：1）药康生物 个股亮点：药康生物是专注实验动物模型的研发创制、生产的高新技术企业，开发拥有自主知识产权的创新小鼠模型，是CRO上游，为CXO企业及创新药企提供基础服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405070802208ae2d5e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405070802208ae2d5e8&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433473838","title":"药康生物：2024Q1海外市场保持快速增长，后续研发重点为斑点鼠和野化鼠项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2433473838","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2433473838?lang=zh_cn&edition=full","pubTime":"2024-05-06 20:25","pubTimestamp":1714998328,"startTime":"0","endTime":"0","summary":"5月6日消息， 药康生物 披露投资者关系活动记录表显示，2024Q1海外市场收入维持了比较快速的增长，海外市场开拓仍然处于摸索阶段，公司也在不断的学习和调整。公司海外市场的基本理念是海外公司要相对独立的发展，因为文化差异比较难打破，所以从去年开始进行了调整。公司后续研发主要重点是斑点鼠项目和野化鼠项目，斑点鼠项目已经进入比较成熟的阶段，未来重点是使用场景开发，野化鼠今年是品系数量迅速扩张的一年，是公司目前最核心的研发项目。此外，公司新设了纽迈生物，提供抗体发现相关服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050620302787d875ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050620302787d875ae&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433108069","title":"药康生物(688046)2023年年报及2024年一季报点评：短期毛利润承压 海外业务持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2433108069","media":"光大证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2433108069?lang=zh_cn&edition=full","pubTime":"2024-05-05 11:09","pubTimestamp":1714878551,"startTime":"0","endTime":"0","summary":"由于公司产能快速扩张，23 年底累计产能达28 万笼，产能利用率处于爬升阶段，公司毛利率较22 年同期下滑3.8pp 至67.6%。目前公司国内产能布局初步到位，随着产能利用率提升，毛利率有望逐步提高。海外业务进展顺利，支持业务高速发展：23 年公司海外业务实现收入0.93 亿元，保持快速增长。公司首个海外设施落地 San Diego，并于2024Q1 启用，将进一步支持公司海外业务发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050511092287d35ee5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050511092287d35ee5&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433174926","title":"东吴证券：给予药康生物买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2433174926","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433174926?lang=zh_cn&edition=full","pubTime":"2024-05-05 09:02","pubTimestamp":1714870930,"startTime":"0","endTime":"0","summary":"东吴证券股份有限公司朱国广,张坤近期对药康生物进行研究并发布了研究报告《2023年报&2024年一季报点评：利润短期承压，海外业务维持高增长》，本报告对药康生物给出买入评级，当前股价为12.72元。最新盈利预测明细如下：该股最近90天内共有7家机构给出评级，买入评级4家，增持评级3家；过去90天内机构目标均价为16.39。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050500000131.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2432016596","title":"药康生物(688046)：利润短期承压 海外业务维持高增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2432016596","media":"东吴证券股份有...","top":-1,"share":"https://www.laohu8.com/m/news/2432016596?lang=zh_cn&edition=full","pubTime":"2024-05-04 09:39","pubTimestamp":1714786767,"startTime":"0","endTime":"0","summary":"利润短期承压，海外业务保持高增长：分业务来看，商品化小鼠模型销售营收3.67 亿元，功能药效营收1.32 亿元，定制繁育营收0.79 亿元，模型定制营收0.35 亿元。受投融资下行引起的需求不振等因素影响，商品化小鼠模型尤其人源化小鼠增速有所放缓；但随着公司小鼠品系丰富、药效服务体系完善，功能药效业务保持了快速增长。扣非净利率有所下行除毛利率下降外还有费用增加影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050409393087d00365&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050409393087d00365&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431366808","title":"药康生物04月30日遭主力抛售239万元 环比增加1891.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431366808","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431366808?lang=zh_cn&edition=full","pubTime":"2024-04-30 15:18","pubTimestamp":1714461492,"startTime":"0","endTime":"0","summary":"04月30日, 药康生物股价跌2.45%，报收12.72元，成交金额5333万元，换手率2.05%，振幅3.76%，量比1.17。药康生物今日主力资金净流出239万元，上一交易日主力净流出12万元，今日环比增加1891.67%。该股近5个交易日上涨7.07%，主力资金累计净流出499万元；近20日主力资金累计净流入394万元，其中净流入天数为11日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301527318b6533c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404301527318b6533c5&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-04-25","address":"江苏省南京市浦口区江北新区学府路12号","stockEarnings":[{"period":"1week","weight":-0.1149},{"period":"1month","weight":0.037},{"period":"3month","weight":-0.1017},{"period":"6month","weight":-0.4064},{"period":"1year","weight":-0.449},{"period":"ytd","weight":-0.4303}],"companyName":"江苏集萃药康生物科技股份有限公司","boardCode":"AI0073","perCapita":"25469股","boardName":"研究和试验发展","registeredCapital":"41000万元","compareEarnings":[{"period":"1week","weight":-0.0101},{"period":"1month","weight":0.0384},{"period":"3month","weight":0.0895},{"period":"6month","weight":0.0223},{"period":"1year","weight":-0.0493},{"period":"ytd","weight":0.0496}],"survey":"　　江苏集萃药康生物科技股份有限公司是一家专业从事实验动物小鼠模型的研发、生产、销售及相关技术服务的高新技术企业，主要产品有商品化小鼠模型销售业务、模型定制业务、定制繁育业务、功能药效业务、代理进出口及其他业务。公司为国内模式动物行业龙头企业之一，是亚洲小鼠突变和资源联盟唯一企业成员、国家科技资源共享服务平台（国家遗传工程小鼠资源库）共建单位，先后被认定为国家级高新技术企业、江苏省博士后创新实践基地、江苏省工程技术研究中心、国家级专精特新小巨人企业等。","serverTime":1715926371868,"listedPrice":22.53,"stockholders":"8007人(较上一季度增加26.31%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药康生物,688046,药康生物股票,药康生物股票老虎,药康生物股票老虎国际,药康生物行情,药康生物股票行情,药康生物股价,药康生物股市,药康生物股票价格,药康生物股票交易,药康生物股票购买,药康生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药康生物(688046)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药康生物(688046)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}